Question-and-Answer Session
Operator
(Operator instructions) Your first question comes from the line of Vivian Cervantes of Rodman and Renshaw.
Vivian Cervantes – Rodman and Renshaw
Hi. Good morning. Thank you for taking the question. Nice performance on the Vita’s platform. Can you give us a little bit of color on the strength in that performance maybe rate that by what contributed most? Is it the FDA issue with BMP [ph]? Is it the clinical data? If you could just provide any color on that, that would be helpful.
Anthony Koblish
Well from the beginning when we launched the Vitoss product in approximately 2002, we decided to take a very fundamentally sound approach to the product that is to say to validate as completely as possible the nature of the performance of the Vitoss Scaffold technology and only decided that we would continue to add value to that Vitoss Scaffold technology by creating new form that we call co-developed with Kensey Nash and also with our sufficient customers to make sure that we’re getting in the handling properties and the forms that they require. And we also had continually invested in the basics of post market surveillance clinical data. Some of the strongest of that data is just starting to come out, and I think in terms of the announcement that we made a month or so ago regarding the continued presentation of our A-list data for Vitoss for Bone Marrow Aspirate versus BMP and also we have period of cervical base data using Vitoss and DNA. So I think that the foundation that we built is strong based on good technology, good clinical data, and how you focus sales organization and I believe it is our foundation that is serving us well right now and will continue to do as well.
Vivian Cervantes – Rodman and Renshaw
Thanks. So you didn’t see any push back into the top macro on the premium processing harnessing of that nature?
Anthony Koblish
The VA product is priced at a premium and we have not seen what is considered to be an appreciable amount of discounting beyond normal pricings in area that we see is very impossible. Our pricing has always held pretty firmly on the A cost product range in general and we can continue to see that trend thus far.
Vivian Cervantes – Rodman and Renshaw
Do you see any benefits at all from the infuse issue and is that – maybe any commentaries from customers that you may have broken with?
- To read the full transcript on Seeking Alpha, click here »
